Research Article
Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity
Table 1
Baseline characteristics of the study population.
| | ć | Overall | LOF | No LOF | value | | ć | | | |
| | Age | 67.0 | 67.0 | 66.0 | 0.7 | | Male gender | 36 (64.3) | 29 (65.9) | 7 (58.3) | 0.7 | | Smoking | 10 (17.9) | 7 (15.9) | 3 (25.0) | 0.4 | | Hypertension | 33 (58.9) | 25 (56.8) | 8 (66.7) | 0.7 | | Diabetes mellitus | 15 (26.8) | 11 (25.0) | 4 (33.3) | 0.7 | | Dyslipidemia | 12 (21.4) | 9 (20.5) | 3 (25.0) | 0.7 | | Prior MI | 3 (5.4) | 1 (2.3) | 2 (16.7) | 0.1 | | Prior PCI | 11 (19.6) | 7 (15.9) | 4 (33.3) | 0.2 | | BMI | 24.8 | 26.1 | 24.3 | 0.2 | | Statin | 15 (26.8) | 13 (29.5) | 2 (16.7) | 0.5 | | -blocker | 9 (16.1) | 5 (11.4) | 4 (33.3) | 0.09 | | ACE inhibitor | 4 (7.1) | 3 (6.8) | 1 (8.3) | 1 | | CCBs | 11 (19.6) | 8 (18.2) | 3 (25.0) | 0.7 | | PPIs | 2 (3.6) | 1 (2.3) | 1 (8.3) | 0.4 | | Platelet count | 215.5 | 221.0 | 215.5 | 1 | | C-reactive protein | 0.1 | 0.1 | 0.1 | 0.2 |
|
|
The denotations are LOF: loss-of-function; MI: myocardial infarction; PCI: percutaneous coronary intervention; BMI: body mass index; ACE: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker; and PPI: proton pump inhibitor.
|
